EUCTR2013-003134-33-ES进行中（未招募）不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women aged 70 years and older
- •2. Are capable, in the investigator's opinion, to complete the study per protocol and have no significant health issues or conditions (including but not limited to severe arthritis of the major lower extremity joints and symptom-limited ambulation) that would impact the capability to get an accurate measurement of study endpoints
- •3. Appendicular lean mass relative to height squared: ?7.23 kg/m² (men); ?5.67 kg/m² (women)
- •4. 4M gait speed <1.0 m/s
- •5. BMI between 18.5 kg/m² and 37 kg/m², inclusive
- •6. Ability to follow the First Step to Active Health program
- •7. Willing and able to comply with clinic visits and study-related procedures
- •8. Provide signed informed consent
- •9. Able to understand and complete study-related questionnaires
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 240
排除标准
- •1. Hospitalization or immobilization with a duration of >48 hours within the month prior to screening
- •2. Surgical procedure requiring general anesthesia within 2 months prior to screening, or a planned surgical procedure requiring general anesthesia within the next 6 months
- •3. Participate in resistance training more than 2 times per week or regular exercise consisting of an average of 30 minutes per day or more of at least moderate physical activity
- •4. Chronic medications introduced within 2 weeks prior to screening
- •5. Weight loss of >10% body weight within 6 months prior to screening
- •6. Respiratory disease (eg, severe chronic obstructive pulmonary disease) that requires oxygen treatment
- •7. Cancer requiring treatment currently or in the past 3 years (except primary nonmelanoma skin cancer or in situ cervical cancer)
- •8. Neurological conditions that are causing impaired muscle function or mobility (may include stroke with residual paresis, paralysis, neuropathy, Parkinson disease, or multiple sclerosis)
- •9. Mini Mental State Exam score of <24
- •10. Active Major Depressive Disorder per Diagnostic and Statistical Manual-V criteria within 3 months prior to screening
- •11. Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia (note: sinus dysrhythmia, asymptomatic block or well controlled atrial fibrillation with normal resting ventricular rate are not exclusion criteria)
- •12. Abnormal echocardiogram findings at screening that are clinically significant, which may include but are not limited to:
- •- Cardiomyopathy
- •- Left ventricular ejection fraction <50%
- •- Moderate or severe diastolic dysfunction, grade II/III
- •- Aortic stenosis
- •- Valvular disease with hemodynamic significance
- •- Left ventricular wall thickness ?1.4 cm (men) and ?1.3 cm (women)
- •13. Uncontrolled diabetes defined as hemoglobin A1C (HbA1C) >10% at screening
- •14. Diastolic blood pressure >100 mm Hg or systolic blood pressure >180 mm Hg (average of 2 readings)
- •15. Alanine aminotransferase (ALT) >3x the upper limit of normal (1 retest allowed)
- •16. Reduced renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m² (1 retest allowed)
- •17. Creatine phosphokinase >5 x the upper limit of normal (1 repeat lab is allowed)
- •18. Use of any prescription or over-the-counter agents known to influence muscle mass or performance within 1 year prior to screening. These may include but are not limited to
- •anabolic steroids, insulin-like growth factor-1 (IGF-1), growth hormone (GH), replacement androgen therapy, and anti-androgen therapy.
- •19. Participation in any clinical trial of small molecule drugs within 30 days prior to screening or biologics within 3 months prior to screening
- •20. Participation within 6 months prior to screening in clinical trials of interventions that are intended to influence muscle mass or performance
- •21. History of human immunodeficiency virus infection
- •22. Positive test for hepatitis B surface antigen and/or hepatitis C antibody at the screening visit
- •23. Pregnant or breastfeeding women
- •24. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more
研究者
相似试验
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, COMPARATIVE, SAFETY AND EFFICACY STUDY OF INTRAVENOUS ZOLEDRONATE (4 AND 8 MG) IN PROSTATE CANCER PATIENTS WITH METASTATIC BONE LESIONS RACEIVING ANTINEOPLASTIC THERAPYPER-011-99OVARTIS BIOSCIENSES PERÚ S.A.,
进行中（未招募）
1 期
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)EUCTR2010-019361-28-ROCB BIOSCIENCES, INC.768
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)EUCTR2010-019361-28-LVCB BIOSCIENCES, INC.900
进行中（未招募）
1 期
MP1032 Treatment in Patients with Moderate to Severe COVID-19EUCTR2021-000344-21-ITMetrioPharm AG120
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)EUCTR2010-019361-28-DECB BIOSCIENCES, INC. A Member of the UCB Group of Companies900